1 Manuscript

1 Epidemiological profile of patients diagnosed with covid-19 in the municipality

2 of São Gonçalo, Rio de Janeiro, Brazil

- 3
- 4 Raphael Rangel das Chagas, M.Sc.¹, Hércules Rezende Freitas, Ph.D.², Sergian Vianna
- 5 Cardozo, Ph.D.¹
- 6
- ¹Interinstitutional Graduate Program in Translational Biomedicine (BIOTRANS), School of Health
 Sciences, Grande Rio University, Duque de Caxias, RJ, Brazil; ²Laboratory of Inborn Errors of
 Metabolism, Leopoldo de Meis Institute of Medical Biochemistry, Federal University of Rio de Janeiro,
 Rio de Janeiro, RJ, Brazil.
- 11
- 12
- 13
- 14 ORCIDS:
- 15
- 16 Raphael Rangel das Chagas: 0000-0002-9503-9439
- 17 Hercules Rezende Freitas: 0000-0003-1584-9157
- 18 Sergian Vianna Cardozo: 0000-0003-2990-7936
- 19
- 20 Authors' e-mail addresses:
- 21
- 22 Raphael Rangel das Chagas: raphael.chagas@unigranrio.edu.br
- 23 Hercules Rezende Freitas: hercules.freitas@bioqmed.ufrj.br
- 24 Sergian Vianna Cardozo: sergian.cardozo@unigranrio.edu.br
- 25
- 26 *Corresponding author: Raphael Rangel das Chagas
- 27
- 28 Interinstitutional Graduate Program in Translational Biomedicine (BIOTRANS),
- 29 School of Health Sciences, Grande Rio University, Duque de Caxias, RJ, Brazil. E-mail
- 30 address: <u>raphael.chagas@unigranrio.edu.br</u>. Phone number: +55 21 99274-1235.
- 31
- 32
- 33

2 Manuscript

34 Abstract

35

Objectives: The global health crisis caused by SARS-CoV-2 has led to over 760 million
confirmed cases and 6.8 million deaths worldwide, primarily impacting the
respiratory system with symptoms varying from mild to severe. This study aimed to
analyze the interplay between vaccination status, sociodemographic profiles,
comorbidities, and COVID-19 outcomes.
Study Design: Observational, cross-sectional, and analytical.

Methods: The study analyzed data from 6,953 individuals, examining vaccination
statuses, sociodemographic profiles, comorbidities, COVID-19 test results, and other
relevant variables. The cohort comprised predominantly mixed-race (51%),
Caucasian (38%), and Black (9.5%) individuals, with 61% being female and 60% aged
between 21-50 years. Prevalent comorbidities included hypertension (18.2%),
diabetes (4.9%), and obesity (0.4%).

Results: Population-weighted analysis revealed significant associations between sociodemographic factors and COVID-19 test outcomes. Younger age groups, particularly 11-30 years, had higher positivity rates, which declined with age. Caucasians exhibited higher positivity rates (40.1%) compared to other ethnicities. Cramér's V indicated small correlations between symptoms and test outcomes, notably with loss of taste (V = 0.11) and smell (V = 0.08). Odds ratio analysis identified

3 Manuscript

53	hypertension as significantly associated with higher COVID-19 positivity (OR = 1.54,
54	95% CI: 1.28-1.83, p < 0.001), while obesity was associated with lower positivity (OR =
55	0.13, 95% CI: 0.02-0.63, p = 0.025). Symptoms such as fever, cough, loss of taste, loss
56	of smell, and myalgia also showed significant associations with positive test
57	outcomes.
58	Conclusions: This study provides valuable insights into the complex interplay of
59	sociodemographic characteristics, comorbidities, symptoms, and COVID-19
60	outcomes.
61	
62	Keywords: SARS-CoV-2; COVID-19; Pandemic; Vaccination; Immunity; Public Health
63	
64	Introduction
65	
66	SARS-CoV-2, a virus from the Coronaviridae family, Betacoronavirus genus, and
67	Sarbecovirus subgenus, causes severe acute respiratory syndrome coronavirus 2
68	(SARS-CoV-2). This enveloped, roughly spherical virus measures 60-140 nm in
69	diameter and has a single strand of positive-sense RNA, about 30,000 nucleotides
70	long ¹ . SARS-CoV-2 is highly contagious, spreading through respiratory droplets and
71	contact with contaminated surfaces ² .

4 Manuscript

The high transmissibility of SARS-CoV-2 led to an outbreak in Wuhan, China, in late 2019, sparking the global COVID-19 pandemic ³. The pandemic has become a significant public health challenge worldwide, resulting in over 760 million confirmed cases and 6.8 million deaths ⁴. The virus primarily affects the respiratory system, with symptoms ranging from mild to severe, including fever, cough, shortness of breath, fatigue, pneumonia, multiple organ failure, and death ⁵.

To combat the pandemic, various measures, including the development of vaccines, have been implemented. Vaccination is a primary strategy to prevent infection and reduce disease severity ^{6,7}. The rapid development of COVID-19 vaccines has involved global efforts, with numerous candidate vaccines in progress ⁸²

The pandemic has disrupted national vaccination schedules, particularly for children under 12 months, causing delays in their vaccinations ¹¹. The continuous development of COVID-19 vaccines is crucial in controlling the virus spread and reducing cases.

In this study, we analyzed data from 6,953 individuals who received COVIDrelated care in São Gonçalo, Rio de Janeiro, Brazil. Our goal was to examine sociodemographic characteristics such as age, ethnicity, and gender in relation to COVID-19 testing results. We also aimed to identify common comorbidities, especially hypertension, among those who tested positive, and to investigate the

- 5 Manuscript
- 92 prevalence of key symptoms, including fever above 38.5°C, loss of smell, and loss of
- 93 taste, among participants who tested positive and negative.

94

- 95 Methods
- 96
- 97 Experimental design
- 98

99 The experimental design of this study is observational, cross-sectional, and 100 analytical. The study population consists of patients who sought care at screening 101 centers in São Gonçalo, a municipality in the state of Rio de Janeiro, Brazil, between 102 July 28, 2021, and December 2, 2021.

103 According to the Brazilian Institute of Geography and Statistics (IBGE), São 104 Gonçalo spans a territorial area of 248.160 km². In 2022, the resident population was 105 estimated at 896,744 people, resulting in a population density of 3,613.57 inhabitants per km². The school enrollment rate for children aged 6 to 14 was 96.7% 106 107 in 2010, and the Municipal Human Development Index (MHDI) was 0.739. 108 Economically, the Gross Domestic Product (GDP) per capita was R\$ 18,504.81 in 109 2021. Infant mortality, a critical health indicator, was 12.33 deaths per thousand live births in 2020¹². 110

6 Manuscript

112 Inclusion criteria and informed consent

113

Patients included in the study exhibited clinical symptoms suggestive of SARS-CoV-2 infection and underwent COVID-19 testing using the RT-LAMP technique. The screening centers in São Gonçalo served as locations for data collection and sample analysis.

This study adhered to the ethical principles outlined in the Declaration of Helsinki and relevant Brazilian legislation. Rigorous measures were implemented to ensure patient confidentiality, with all data anonymized before analysis. The research protocol was reviewed and approved by the Research Ethics Committee of the University of Grande Rio (CEP/UNIGRANRIO) under CAAE number 32362220.1.0000.5283.

All participants were thoroughly informed about the study's objectives and potential risks and provided written informed consent to participate. Participation was voluntary, with no coercion or pressure applied, and participants retained the right to withdraw their consent at any time without facing any adverse consequences. The study was conducted following the highest ethical standards, ensuring the integrity and dignity of both participants and researchers.

130

131 Data collection

7 Manuscript

132

Data collection at screening centers in São Gonçalo, Rio de Janeiro, included sociodemographic characteristics, comorbidities, COVID-19 symptoms, vaccination history, and COVID-19 test results. Patient age was determined by recording the date of birth and the date of sample collection. Ethnicity was documented to understand ethnic diversity. Comorbidities such as hypertension, diabetes, and obesity were detailed, along with other comorbidities.

The onset date of COVID-19 symptoms and specific symptoms reported, including runny nose, fever, loss of smell and taste, diarrhea, headache, shortness of breath, muscle pain, and cough, were recorded. COVID-19 test results, using the RT-LAMP technique, were documented as positive or negative. The number of COVID-19 vaccine doses received, the type of vaccine administered, and the date of administration were also recorded.

Healthcare professionals, adhering to safety and ethical protocols, conducted data collection. Participants were informed about the data collection purpose and provided written informed consent. Data confidentiality was maintained, and information was handled anonymously.

149

150 Statistical analysis

8 Manuscript

152	The statistical analysis for this study was conducted using RStudio (version					
153	2023.06.1 + 524) with the R programming language (version 4.2.2).					
154	Through univariate analysis, we aimed to describe the profile of the					

Through univariate analysis, we aimed to describe the profile of the participants, identify the number of non-responses, and detect outliers. Data presented in Tables 1 to 6 include the analysis of sociodemographic characteristics, comorbidities, COVID-19 test results, and other relevant variables. This analysis was conducted using absolute and relative frequencies as well as mean values.

Bivariate analysis was performed to examine significant associations between study variables. Considerring that the data was collected from a convenience sample, weights were calculated by post-stratification based on the known populational (IBGE, 2024) ethnicity and sex distributions. Then, the Pearson's chisquare test (χ^2) with Rao & Scott adjustment was employed to evaluate the associations between study variables:

165

166
$$\chi^2_{\omega} = \frac{\left(\sum \frac{(O_{ij} - E_{ij})^2}{E_{ij}}\right)}{D_{ef}}$$

167

168 Where χ^2_{ω} represents the (weighted) adjusted chi-square test statistic, *Oij* 169 denotes the observed frequency counts, *Eij* denotes the expected frequency counts, 170 and D_{ef} is the calculated design effect. This methodological approach is consistent

9 Manuscript

171 with the literature on statistical data analysis in health, as highlighted by ¹³, who
172 emphasize the importance of univariate and bivariate analyses and the application

173 of the Pearson chi-square test for categorical variable associations.

174 Additionally, to assess the strength of associations identified by the χ^2 test, a

176

175

177
$$V_{\omega} = \sqrt{\frac{\chi^2_{\omega}}{N_{\omega} \times \min(r-1, c-1)}}$$

weighted Cramer's V was calculated:

178

179 Where V_{ω} indicates the strength of association between variables (Cramer's 180 V), χ^2_{ω} is the weighted χ^2 test statistic, N $_{\omega}$ is the total weight (sum of all weights), *r* is the 181 number of rows in the contingency table, and *c* is the number of columns in the 182 contingency table. For interpretive purposes, χ^2_{ω} and V_{ω} values with *p* less than 0.05 183 were considered statistically significant, allowing for the rejection of the null 184 hypothesis.

Finally, to analyze the relationship between various study variables, odds ratios (OR) were calculated, providing a measure of association between exposure variables and the outcome variable, which in this case is the result of the COVID-19 test. The OR was calculated as:

10 Manuscript

190
$$L(\beta) = \sum_{i=1}^{n} \omega_i [y_i \log(p_i) + (1 - y_i) \log(1 - p_i)]$$

 $OR = e^{\beta_j}$

193

194 Where $L(\beta)$ is the log-likelihood function, p_i is the predicted probability that $Y_i =$ 195 1, *OR* is the weighted odds ratio for a given predictor, and β_i is the estimated 196 coefficient for the predictor. For each calculated OR, a 95% confidence interval (CI) 197 was also computed to assess the precision of the estimate. Also, for interpretative 198 purposes, a p-value less than 0.05 considered statistically significant. This approach 199 ensures that the identified associations are less likely to derive from random chance. 200

201 Results

202

Table 1 details the sociodemographic characteristics of the study participants, categorizing them by age group, ethnicity, and gender. Age groups ranged from 10 to 81 years and above. Ethnicity was classified into mixed-race (parda), Caucasian, Black, other, and unknown. The data indicate that most participants were mixed-race (51%), followed by Caucasian (38%) and Black (9.5%). Furthermore, a significant proportion of the participants were female (61%). Age-wise, the largest group was

- 11 Manuscript
- aged 21 to 50 years, comprising approximately 60% of the participants. Those aged
- 210 61 to 80 years constituted around 14%, while participants aged 81 years or older
- 211 made up about 1% of the total sample.
- 212 Key comorbidities (*i.e.*, obesity, hypertension, and type II diabetes) were also
- 213 examined (Supplementary table 1). Most participants did not report having diabetes
- 214 (95.1%), obesity (99.6%), or hypertension (81.8%). Among the comorbidities
- 215 reported, hypertension was the most prevalent (18.2%), followed by diabetes (4.9%)
- and obesity (0.4%). This highlights hypertension as the most common comorbidity
- 217 within the study population.
- 218

219 **Table 1**. Sociodemographic characteristics of the cohort of participants (patients)

- 220 who were attended at the screening centers of São Gonçalo (RJ), during the period
- 221 from 07/28/2021 to 12/02/2021.

Variables	$N = 6,953^{1}$
AGE	
≤ 10 y.o.	10 (0.1%)
11 to 20 y.o.	491 (7.1%)
21 a 30 y.o.	1,419 (20%)
31 a 40 y.o.	1,406 (20%)
41 a 50 y.o.	1,457 (21%)
51 a 60 y.o.	1,142 (16%)
61 a 70 y.o.	679 (9.8%)
71 a 80 y.o.	274 (3.9%)
≥ 81 y.o.	75 (1.1%)
ETHNICITY	
Brown	3,490 (51%)
Caucasian	2,625 (38%)
Black	652 (9.5%)
Other	88 (1.3%)
Not available	98
SEX	
Female	4,263 (61%)
Male	2,690 (39%)

12 Manuscript

Variables	$N = 6,953^{1}$
¹ n (%)	

222

223	Table 2 presents additional variables beyond the comorbidities and
224	sociodemographic characteristics of the study participants. It details the number of
225	participants who experienced symptoms such as fever, runny nose, loss of smell, loss
226	of taste, diarrhea, headache, shortness of breath, and muscle pain. The table also
227	provides information on the participants' vaccination status, including the number
228	of doses received and the type of vaccine administered.
229	The data indicate that most participants did not have a fever above 38.5°C
230	(73.4%), runny nose (65.6%), loss of smell (86%), or loss of taste (85.9%). Moreover,
231	the majority received two vaccine doses (62.5%), with the Oxford-AstraZeneca
232	vaccine being the most administered (45%). Among the variables examined,
233	headache was the most frequently reported symptom, affecting 49% of the
234	participants.

235

Table 2. Symptoms, immunization, and geographical distribution in the sample of
participants (patients) who were attended at the screening centers of São Gonçalo
(RJ), during the period from 07/28/2021 to 12/02/2021.

Variables	$N = 6,953^{1}$
FEVER < 38.5 °C	
No	5,057 (73%)
Yes	1,828 (27%)
Not available	68
$FEVER \ge 38.5 \ ^{\circ}C$	
No	5,893 (86%)
Yes	989 (14%)

13 Manuscript

Variables	N = 6,953 ¹
Not available	71
RHINITIS	
No	4,496 (65%)
Yes	2,382 (35%)
Not available	75
LOSS OF SMELL	
No	5,908 (86%)
Yes	956 (14%)
Not available	89
LOSS OF TASTE	
No	5,912 (86%)
Yes	968 (14%)
Not available	73
DIARRHEA	
No	6.354 (92%)
Yes	544 (7.9%)
Not available	55
HEADACHE	
No	3,483 (51%)
Yes	3,414 (49%)
Not available	56
DYSPNEA	
No	6 052 (88%)
Ves	874 (12%)
Not available	77
MYALGIA	
No	4,556 (66%)
Yes	2,316 (34%)
Not available	81
COUGH	
No	3.268 (48%)
Yes	3.580 (52%)
Not available	105
RESULT	
Negative	4,925 (72%)
Positive	1,953 (28%)
Not available	75
DOSE	
Unvaccinated	53 (1.0%)
First dose	1,578 (30%)
Second dose	3,298 (62%)
Third dose	206 (3.9%)
Single dose	142 (2.7%)
Not available	1,676
VACCINE	·
Oxford - AstraZeneca	2,352 (45%)
Coronavac - Sinovac	1,163 (22%)
Pfizer - BNT162b2	1,532 (29%)
Janssen-Cilag	149 (2.9%)

14 Manuscript

Variables	N = 6,953 ¹
Not available	1,757
MUNICIPALITY	
São Gonçalo	6,851 (99%)
Other	102 (1.5%)
VACCINATED	
No	53 (1.0%)
Yes	5,224 (99%)
Not available	1,676
¹ n (%)	

239

240 Table 3 shows the relationship between the sociodemographic profile of 241 participants and their COVID-19 test results, detailing age, ethnicity, and gender. 242 Younger individuals, specifically those aged 11-20 years, showed a higher positivity 243 rate (7.4%) compared to the negative group (6.8%). This trend continued with the 21-244 30 years (18.0% positive) and 31-40 years (17.8% positive) groups, though these 245 groups also had substantial negative test rates (21.3% and 21.1%, respectively). 246 Positivity rates decreased with age, with a notable difference in the 71-80 years 247 group (6.8% positive vs. 2.8% negative). The 81+ years group had 1.3% positive and 248 1.0% negative.

Ethnicity showed significant variations. The brown ethnic group had nearly half (49.9%) test positive, slightly lower than the negative group (51.2%). Caucasians had a higher positivity rate (40.1%) compared to their negative counterparts (37.7%). The black ethnic group had a slightly lower positivity rate (8.8%) compared to the negative group (9.8%). Other ethnicities had almost identical positive (1.2%) and

- 15 Manuscript
- 254 negative (1.3%) rates. A small portion lacked ethnic classification, which did not
- 255 significantly impact overall trends.
- 256 Gender analysis revealed no significant differences. Females constituted
- 257 57.9% of positive cases and 62.9% of negative cases. Males represented 42.1% of
- 258 positive cases and 37.1% of negative cases.
- 259
- 260 **Table 3**. Relationship between the sociodemographic profile and the COVID-19 test
- 261 results of participants (patients) who were attended at the screening centers of São
- 262 Gonçalo (RJ), during the period from 07/28/2021 to 12/02/2021.

	COVID-19 TEST RESULT			
Variables	TOTAL , N = 6,878 ¹	NEGATIVE , N = 4,925 ¹	POSITIVE , N = 1,953 ¹	p-value ²
AGE				0.000*
≤ 10 y.o.	10 (0.1%)	6 (0.1%)	4 (0.2%)	
11 to 20 y.o.	482 (7.0%)	337 (6.8%)	145 (7.4%)	
21 a 30 y.o.	1,399 (20.3%)	1,048 (21.3%)	351 (18.0%)	
31 a 40 y.o.	1,386 (20.2%)	1,039 (21.1%)	347 (17.8%)	
41 a 50 y.o.	1,441 (21.0%)	1,063 (21.6%)	378 (19.4%)	
51 a 60 y.o.	1,137 (16.5%)	796 (16.2%)	341 (17.5%)	
61 a 70 y.o.	676 (9.8%)	448 (9.1%)	228 (11.7%)	
71 a 80 y.o.	272 (4.0%)	139 (2.8%)	133 (6.8%)	
≥ 81 y.o.	75 (1.1%)	49 (1.0%)	26 (1.3%)	
ETHNICITY				0.002*
Brown	3,446 (50.8%)	2,490 (51.2%)	956 (49.9%)	
Caucasian	2,605 (38.4%)	1,836 (37.7%)	769 (40.1%)	
Black	646 (9.5%)	478 (9.8%)	168 (8.8%)	
Other	84 (1.2%)	61 (1.3%)	23 (1.2%)	
Not available	97	60	37	
SEX				0.394
Female	4,226 (61.4%)	3,096 (62.9%)	1,130 (57.9%)	
Male	2,652 (38.6%)	1,829 (37.1%)	823 (42.1%)	

¹n (%)

²Pearson χ^2 test

16 Manuscript

Table 4 illustrates the relationship between comorbidities and COVID-19 test results. It details the number of participants who reported having hypertension, diabetes, and obesity, as well as the number of participants who tested positive or negative for COVID-19 within each comorbidity group.

The analysis of comorbidities and their association with COVID-19 test results provides several key insights. Hypertension did not show a significant link to COVID-19 test outcomes. Among those without hypertension, the positive test rate was 81.9%, nearly identical to the negative test rate of 81.8%. Similarly, 18.1% of individuals with hypertension tested positive, compared to 18.2% who tested negative.

Diabetes also did not exhibit a significant correlation with COVID-19 test results. The data showed that 95.1% of individuals without diabetes tested positive, while 95.0% tested negative. Among those with diabetes, 4.9% tested positive compared to 5.0% negative. In contrast, obesity showed a significant association with COVID-19 test results. The overwhelming majority of individuals without obesity tested positive (99.7%) and negative (99.5%). However, among those with obesity, only 0.3% tested positive compared to 0.5% negative.

281

282 **Table 4**. Comorbidities and COVID-19 test results.

17 Manuscript

		COVID-19 TE	EST RESULT	
Variables	TOTAL , N = 6,878 ¹	NEGATIVE , N = 4,925 ¹	POSITIVE , N = 1,953 ¹	p- value ²
HYPERTENSION				0.578
No	5,623 (81.8%)	4,026 (81.8%)	1,597 (81.9%)	
Yes	1,250 (18.2%)	896 (18.2%)	354 (18.1%)	
Not available	5	3	2	
DIABETES				0.230
No	6,529 (95.1%)	4,674 (95.0%)	1,855 (95.1%)	
Yes	339 (4.9%)	244 (5.0%)	95 (4.9%)	
Not available	10	7	3	
OBESITY				0.000*
No	6,825 (99.6%)	4,884 (99.5%)	1,941 (99.7%)	
Yes	29 (0.4%)	23 (0.5%)	6 (0.3%)	
Not available	24	18	6	
¹ n (%)				

²Pearson χ^2 test

283

Table 5 shows the relationship between symptoms, vaccination status, and COVID-19 test results. It categorizes participants based on the presence of fever >38.5°C, runny nose, loss of smell, loss of taste, diarrhea, headache, shortness of breath, muscle pain, and cough, as well as their vaccination status, and compares the number of positive and negative test results.

A significant proportion of positive cases had fever >38.5°C (15.8%), fever $\leq 38.5^{\circ}C$ (34.9%), loss of smell (29.3%), and loss of taste (26.6%). Most negative cases did not have these symptoms. Dyspnea was more common in negative cases (13.1% vs. 9.1%), while myalgia was more frequent in positive cases (37.4% vs. 32.3%).

293 Regarding vaccination, 36.8% of first-dose recipients tested positive, while 294 27.4% tested negative. For second-dose recipients, 54.4% tested positive, and 65.4% 295 tested negative. Third-dose recipients had a positive test rate of 4.5%, slightly higher

- 18 Manuscript
- than the negative rate of 3.7%. Single-dose recipients had an identical positive and
- 297 negative rate of 2.7%.
- 298 The type of vaccine did not show a significant association with test results.
- 299 Among Oxford-AstraZeneca recipients, 43.7% tested positive, and 46.0% tested
- 300 negative. CoronaVac-Sinovac had a positive rate of 27.1% and a negative rate of
- 301 20.7%. Pfizer-BNT162b2 had a positive rate of 26.3% and a negative rate of 30.4%.
- 302 Janssen-Cilag had a positive rate of 2.9% and a negative rate of 2.8%. This suggests
- 303 comparable effectiveness across different vaccines.
- 304 Overall vaccination status significantly related to test results. Among the
- 305 unvaccinated, 1.6% tested positive, while 0.8% tested negative.
- 306

Table 5. Other variables and the COVID-19 test results of participants (patients) who
 were attended at the screening centers of São Gonçalo (RJ), during the period from
 07/28/2021 to 12/02/2021.

	COVID-19 TEST RESULT			
Variables	TOTAL, N =	NEGATIVE, N =	POSITIVE, N =	p-
	6,878 ¹	4,9 25 ¹	1,953 ¹	value ²
FEVER < 38.5 °C				0.002*
No	5,034 (73.4%)	3,766 (76.7%)	1,268 (65.1%)	
Yes	1,824 (26.6%)	1,143 (23.3%)	681 (34.9%)	
Not available	20	16	4	
$FEVER \ge 38.5 \ ^{\circ}C$				0.002*
No	5,873 (85.7%)	4,229 (86.3%)	1,644 (84.2%)	
Yes	982 (14.3%)	674 (13.7%)	308 (15.8%)	
Not available	23	22	1	
RHINITIS				0.059
No	4,490 (65.6%)	3,081 (62.8%)	1,409 (72.5%)	
Yes	2,359 (34.4%)	1,824 (37.2%)	535 (27.5%)	
Not available	29	20	9	
LOSS OF SMELL				0.000*

19 Manuscript

		COVID-19 T		
	TOTAL, N =	NEGATIVE, N =	POSITIVE, N =	p-
variables	6,8 78 ¹	4,9 25 ¹	1,953 ¹	value ²
No	5,880 (86.0%)	4,506 (92.1%)	1,374 (70.7%)	
Yes	955 (14.0%)	385 (7.9%)	570 (29.3%)	
Not available	43	34	9	
LOSS OF TASTE				0.000*
No	5,886 (85.9%)	4,460 (90.9%)	1,426 (73.4%)	
Yes	965 (14.1%)	447 (9.1%)	518 (26.6%)	
Not available	27	18	9	
DIARRHEA				0.097
No	6,326 (92.1%)	4,522 (91.9%)	1,804 (92.5%)	
Yes	543 (7.9%)	397 (8.1%)	146 (7.5%)	
Not available	9	6	3	
HEADACHE				0.198
No	3,464 (50.4%)	2,414 (49.1%)	1,050 (53.8%)	
Yes	3,404 (49.6%)	2,504 (50.9%)	900 (46.2%)	
Not available	10	7	3	
DYSPNEA				0.005*
No	6,027 (88.0%)	4,259 (86.9%)	1,768 (90.9%)	
Yes	820 (12.0%)	642 (13.1%)	178 (9.1%)	
Not available	31	24	7	
MYALGIA				0.040*
No	4,532 (66.2%)	3,312 (67.7%)	1,220 (62.6%)	
Yes	2,311 (33.8%)	1,581 (32.3%)	730 (37.4%)	
Not available	35	32	3	
COUGH				0.818
No	3,265 (47.9%)	2,358 (48.2%)	907 (47.0%)	
Yes	3,555 (52.1%)	2,531 (51.8%)	1,024 (53.0%)	
Not available	58	36	22	
DOSE				0.002*
Unvaccinated	53 (1.0%)	31 (0.8%)	22 (1.6%)	
First dose	1,569 (29.9%)	1.057 (27.4%)	512 (36.8%)	
Second dose	3.280 (62.5%)	2.524 (65.4%)	756 (54.4%)	
Third dose	206 (3.9%)	144 (3.7%)	62 (4.5%)	
Single dose	141 (2.7%)	103 (2.7%)	38 (2.7%)	
Not available	1.629	1.066	563	
VACCINE	_,	_,		0.572
Oxford - AstraZeneca	2.347 (45.4%)	1.750 (46.0%)	597 (43.7%)	
Coronavac - Sinovac	1,158 (22,4%)	788 (20.7%)	370 (27.1%)	
Pfizer - BNT162b2	1.515 (29.3%)	1,156 (30,4%)	359 (26.3%)	
Janssen-Cilag	148 (2.9%)	108 (2.8%)	40 (2 9%)	
Not available	1 710	1 123	587	
VACCINATED	1,710	1,120	507	0 014*
No	53 (1 0%)	31 (0.8%)	22 (1.6%)	0.017
Ves	5 196 (99 0%)	3 828 (99 2%)	1 368 (98 4%)	
103	5,150 (55.070)	5,020 (55.270)	1,500 (50.470)	

20 Manuscript

COVID-19 TEST RESULT			EST RESULT	
Variables	TOTAL , N = 6,878 ¹	NEGATIVE , N = 4,925 ¹	POSITIVE , N = 1,953 ¹	p- value ²
Not available	1,629	1,066	563	
¹ n (%)				

²Pearson χ^2 test

310

311	In addition to analyzing the independence of the study variables, the strength
312	of the associations between the variables of interest and parameters such as
313	ethnicity, vaccination status, and the number of vaccine doses received was
314	evaluated using the same sample.
315	As depicted in Figure 1, loss of taste and smell show the greater (although
316	weak) correlations with the test results (Cramér's V = 0.08 and 0.11 , respectively).
317	Low and high fever (highly intercorrelated, $V = 0.25$), as well as dyspnea, showed
318	equaly negligible (although significant) correlations with test results (Cramér's V =
319	0.04). Finally, myalgia was the symptom with the smaller significant correlation with
320	test results (Cramér's V = 0.03).

321

Figure 1. Heatmap of the magnitude of association (weighted Cramer's V) betweenthe study variables and vaccination parameters, ethnicity, and vaccine dose.

21 Manuscript





327

Here, we also calculated odds ratios for various study variables against COVID-19 test results, shown in Figure 2. Hypertension was significantly associated with higher likelihood of testing positive (OR = 1.54, 95% CI: 1.28-1.83; p = 2.67^{-6}). Diabetes showed a trend towards higher likelihood but was not significant (OR =

22 Manuscript

332 1.30, 95% CI: 0.97-1.73; p = 0.078). Obesity was associated with a significantly lower 333 likelihood (OR = 0.13, 95% CI: 0.02-0.63; p = 0.025). Fever >38.5°C had a strong association (OR = 2.55, 95% CI: 2.17-3.00; $p = 9.26^{-30}$), and fever $\leq 38.5^{\circ}$ C also showed 334 significant association (OR = 2.11, 95% CI: 1.80-2.48; $p = 6.68^{-20}$). Rhinitis was linked to 335 336 lower likelihood (OR = 0.68, 95% CI: 0.59-0.78; $p = 3.94^{-8}$). Loss of smell (OR = 3.65, 95% CI: 2.91-4.59; p = 8.48⁻²⁹) and loss of taste (OR = 2.05, 95% CI: 1.62-2.57; p = 1.14 337 338 ⁻⁹) were strong indicators of positive tests. 339 Diarrhea showed a non-significant trend towards lower likelihood (OR = 0.82, 340 95% CI: 0.65-1.04; p = 0.107). Headache showed no significant association (OR = 1.05, 341 95% CI: 0.92-1.20; p = 0.483). Dyspnea was strongly associated with lower likelihood (OR = 0.33, 95% CI: 0.26-0.43; p = 7.21⁻¹⁸). Myalgia (OR = 1.31, 95% CI: 1.15-1.50; p = 342 343 7.38⁻⁵) and cough (OR = 1.42, 95% CI: 1.25-1.62; $p = 1.43^{-7}$) were significantly 344 associated with higher likelihood. Being male was also associated with higher 345 likelihood (OR = 1.23, 95% CI: 1.08-1.40; p = 0.002).

346

Figure 2. Weighted odds ratios evaluating study variables against covid-19 testresults.

23 Manuscript



350

349

- 351 Discussion
- 352
- 353 Sociodemographic Variables

24 Manuscript

355	Age, race, ethnicity, and gender significantly impact COVID-19 infection and
356	outcomes. According to Table 4, 74.5% of individuals who tested positive for COVID-
357	19 were over 31 years old, with the highest prevalence among those aged 41 to 50
358	years (19.4%). Age significantly influences COVID-19 status and progression, with
359	individuals over 65 exhibiting elevated viral loads, higher pro-inflammatory markers,
360	and reduced immune response efficiency due to factors like inflammation,
361	immunological aging, and changes in ACE2 receptor dynamics and cytokine profiles
362	¹⁴ . The mental state of the elderly can also impact their recovery ¹⁵ .
363	Racial and ethnic minority groups have been disproportionately affected by
364	the pandemic ¹⁶ . In the current cohort, 59.9% of those testing positive for COVID-19
365	identified as non-white (mixed race, Black, and other ethnicities). African Americans,
366	Hispanics, and non-Hispanic Blacks have higher infection rates than other racial and
367	ethnic groups ^{17,18} . Socioeconomic status and healthcare access significantly
368	contribute to these disparities. Lower to middle socioeconomic status is linked to
369	higher COVID-19 hospitalization rates ¹⁹ . Non-white participants face increased
370	exposure risks and healthcare barriers, leading to higher chances of seroconversion
371	and hospitalization ²⁰ . These findings highlight the need for equitable resource
372	distribution and targeted interventions to address COVID-19's disproportionate
373	impact on racial and ethnic minority groups.

25 Manuscript

374 Data from ten European countries indicate that working-age women have 375 higher COVID-19 diagnosis rates than men, with the trend reversing after retirement. Women's higher infection rates may be due to their greater 376 representation in healthcare-related occupations ²¹. In the current study, 57.9% of 377 individuals testing positive for COVID-19 were female. The relationship between 378 379 gender and COVID-19 infection is complex and multifaceted. Research shows 380 gender disparities in vulnerability, severity, and outcomes of COVID-19. Despite men being more susceptible to severe infection outcomes, including 381 higher 382 hospitalization and mortality rates compared to women²², women, due to genetic 383 and hormonal factors, exhibit a more resilient immune response. Women's expression of the TLR7 gene on the X chromosome enhances their ability to produce 384 385 antiviral proteins and interferons in dendritic cells, protecting them against severe 386 SARS-CoV-2 infections ²². Additionally, cardiovascular conditions significantly affect 387 COVID-19 outcomes, with men exhibiting greater vulnerability compared to women 23. 388

389

390 Comorbidities

391

392 Hypertension is a primary risk factor for adverse COVID-19 outcomes, 393 associated with severe illness and increased mortality. In ²⁴ , 74% of hypertensive

26 Manuscript

patients with moderate symptoms died, with a relative risk (RR) of 1.45 (CI 0.96-2.2).
²⁵ reported a hazard ratio (HR) of 1.58 (CI 1.07-2.32) linked to hypertension, and any
comorbidity presence was associated with an HR of 1.79 (CI 1.16-2.77). Another
study found a 22% odds ratio (OR) (1.22; CI 1.12-1.33) increase in severe infection
among hypertensive patients. Both hypertensive (>180 mm/Hg, OR 1.93; CI 1.063.51) and hypotensive (<120 mm/Hg, OR 1.40; CI 1.11-1.78) patients had higher
chances of severe COVID-19 ²⁶.

401 Hypertension may increase the risk of contracting COVID-19. For instance, in a 402 study of 140 hospitalized COVID-19 patients, 30% had hypertension ²⁷. Another study with 1099 confirmed COVID-19 patients reported hypertension in 23.7% ²⁸. However, 403 404 these studies do not establish a causal relationship between hypertension and 405 COVID-19 infection. Conversely, other studies found no significant association 406 between hypertension and COVID-19 infection risk. A retrospective study of 1178 407 hospitalized COVID-19 patients in Wuhan found no difference in hypertension 408 prevalence (30.7%) between severe and non-severe cases or survivors and non-409 survivors, suggesting hypertension and ACE inhibitor use may not significantly increase infection risk ²⁹. 410

Diabetes is strongly associated with severe symptoms, worse outcomes, and higher mortality in COVID-19 patients. Patients with diabetes often have poorer prognoses and increased susceptibility to infections due to complications like

27 Manuscript

414 peripheral neuropathy and vascular insufficiency, nearly doubling the risk of death 415 ³⁰⁻³³. Recent-onset hyperglycemia and new-onset diabetes have been reported in 416 COVID-19 patients without pre-existing diabetes, suggesting a bidirectional 417 interaction ³⁴⁻³⁶. However, whether people with diabetes are inherently more prone 418 to COVID-19 infection remains unclear. Overall, diabetes is consistently associated 419 with worse outcomes and increased mortality.

420 Obesity is also linked to severe COVID-19 outcomes and mortality ³⁷. Studies 421 show obese patients are more likely to develop severe disease and require invasive mechanical ventilation ^{38,39}. Obesity reduces cardiorespiratory reserves and 422 423 exacerbates immune dysfunction, increasing risks of hospitalization, respiratory 424 infections, airway diseases, fatty liver, hypertension, depression, type 2 diabetes, cardiovascular diseases, and cancer ⁴⁰. An extensive review identified obesity as a 425 426 risk factor for severe COVID-19, with patients having BMI >40 kg/m² showing higher 427 odds for mechanical ventilation (2.17; CI 1.59-2.97) and mortality (1.67; CI 1.39-2.00) 41. 428

In the present study, hypertension was the most common comorbidity (18.1% of infected patients), followed by diabetes (4.9%) and obesity (0.3%). Only obesity frequencies differed significantly between negative and positive patients (0.5% vs. 0.3%, χ^2 p = 0.000).

28 Manuscript

434 Symptomatology

435

cough, fatique, shortness 436 Fever, anosmia, ageusia, of breath, 437 myalgia/arthralgia, chills, nausea/vomiting, nasal congestion, diarrhea, abdominal pain, hemoptysis, and conjunctival congestion are common COVID-19 symptoms 438 ^{42,43}. Gastrointestinal symptoms like nonspecific abdominal pain, watery diarrhea, 439 and ileus have also been reported ⁴⁴. Pulmonary symptoms include pneumonia, 440 441 ARDS, and respiratory failure, while arrhythmias and neurological symptoms are extrapulmonary manifestations ⁴⁵. Long-term symptoms include lethargy, difficulty 442 concentrating, and cough. Prolonged symptoms one month post-infection are 443 associated with being female, having chronic lung disease, and hypertension ⁴⁶. 444

445 COVID-19 requires differential diagnosis due to nonspecific symptoms ⁴⁷. It 446 includes other respiratory diseases like influenza and pre-existing lung pathologies 447 ⁴⁸. Symptoms such as cough, fever, shortness of breath, and headache overlap with other respiratory infections and flu-like illnesses ⁴⁹. Radiological features of COVID-448 ground-glass 449 19 pneumonia, like opacities, crazy-paving patterns, and consolidations, challenge differential diagnosis ⁵⁰. A multidisciplinary approach and 450 451 specific diagnostic tests, such as SARS-CoV-2 antigen determination, are crucial for 452 accurate diagnosis.

29 Manuscript

453	In the present study, the most prevalent symptoms in positive patients were
454	high fever (≥ 38.5°C; 15.8%, p = 0.002), low fever (< 38.5°C; 34.9%, p = 0.002), loss of
455	smell (29.3%, p = 0.000), loss of taste (26.6%, p = 0.000), and myalgia (37.4%, p < 0.04).
456	Testing positive for COVID-19 is linked to symptoms like fever (both high and low),
457	loss of smell, loss of taste, and myalgia, as documented in the literature ⁵¹ . Myalgia,
458	common in viral disorders and other inflammatory conditions, often presents in
459	patients with hypertension and fever, indicating a systemic response to infections ⁵² .
460	Changes in taste and smell, distinctive of COVID-19 $^{\rm 53}$, are also associated with
461	metabolic conditions like obesity, where systemic inflammation can affect sensory
462	function ⁵⁴ . High fever, a marker of systemic inflammatory response, can signal
463	complications in patients with hypertension or diabetes, where inadequate control
464	of underlying conditions may predispose to complications ⁵⁵ .
465	

466 Vaccination

467

Table 5 highlights a significant relationship between the number of vaccine doses and negative COVID-19 test outcomes (p = 0.002). COVID-19 vaccination status (vaccinated or not vaccinated) was significantly linked to test results (negative or positive) (p = 0.014, Pearson's χ^2 test). These findings underscore that vaccination significantly reduces the risk of testing positive for COVID-19, with most positive

30 Manuscript

473 cases occurring in unvaccinated individuals, while the majority of vaccinated 474 individuals test negative.

Independent evidence supports this relationship. Studies have indicated a 475 476 higher proportion of COVID-19 positive cases among unvaccinated individuals compared to those who have received at least one vaccine dose ⁵⁶. Additionally, 477 478 vaccination has been shown to reduce risks of hospitalization, ICU admissions, and oxygen requirement ⁵⁷. Vaccination plays a pivotal role in mitigating severe COVID-19 479 480 cases, especially in fully vaccinated individuals. Social determinants such as age, 481 income, education, and migration history also influence COVID-19 vaccination 482 uptake, with higher rates among older adults, individuals with higher education and income levels, and lower rates among those with a migration history ⁵⁸. Recent 483 484 clinical trials have underscored the efficacy of mRNA vaccines in preventing virus 485 infection ⁵⁹. These insights highlight the critical role of vaccination in preventing 486 COVID-19 infection and reducing disease severity.

487

488 Final remarks

489

490 Our data offers a comprehensive view of sociodemographic characteristics,
491 comorbidities, symptoms, and COVID-19 test outcomes among participants. Key
492 findings include:

31 Manuscript

493

494	•	Participants were predominantly of mixed race, followed by Caucasian and
495		Black individuals, with females outnumbering males. The age group 21-50
496		years was most represented, while those 81 years or older were least
497		represented.
498	•	Most participants did not report hypertension, diabetes, or obesity, although

- 499 hypertension was the most prevalent among those who did.
- Reported symptoms varied widely, with headache being the most common.
- 501 Fever above 38.5°C, loss of smell, and loss of taste were frequent among
- 502 those testing positive for COVID-19, but a significant proportion of positive
- 503 cases did not show these symptoms.
- Age significantly affected the likelihood of testing positive.
- Hypertension was more commonly associated with positive COVID-19 tests
 among participants with comorbidities, while diabetes and obesity were less
 prevalent among those testing positive.
- Fever, loss of smell, loss of taste, and headache were key indicators of
 infection. Vaccination significantly reduced positive test rates, with a higher
 proportion of unvaccinated participants testing positive.

- 32 Manuscript
- 512 In conclusion, these insights can guide targeted strategies for prevention,
- 513 screening, and treatment, and identify at-risk populations.
- 514
- 515 Acknowledgements
- 516
- 517 Ethical approval
- 518
- 519 The present research protocol was reviewed and approved by the Research
- 520 Ethics Committee of the University of Grande Rio (CEP/UNIGRANRIO) under CAAE
- 521 number 32362220.1.0000.5283.
- 522
- 523 Conflicts of interest
- 524
- 525 Authors declare having no conflicts of interest.
- 526
- 527 Funding
- 528

529 This work was supported by the National Council for Scientific and 530 Technological Development (CNPq, Brazil) [152071/2020-2], the Tess Research 531 Foundation (TRF, USA), [Early-Career Investigator Research Grant 2022/2023], the

- 33 Manuscript
- 532 Carlos Chagas Filho Research Support Foundation of the State of Rio de Janeiro
- 533 (FAPERJ) [Emergencial E-26/211.041/2021 and JCNE E-26/201.434/2021].

534

535 **References**

- 537 1. Khalil OAK, Khalil SDS. SARS-CoV-2: taxonomia, origem e constituição. Rev Med
 538 (São Paulo). 2020 Dec 10;99(5):473–9.
- Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A,
 Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared
 with SARS-CoV-1. N Engl J Med. 2020 Apr 16;382(16):1564–7.
- World Health Organization. Novel Coronavirus (2019-nCoV) SITUATION
 REPORT 1 [Internet]. World Health Organization; 2020 [cited 2023 Sep 9] p. 5.
 Report No.: 1. Available from:
- 545 https://www.who.int/docs/default-source/coronaviruse/situation-reports/546 20200121-sitrep-1-2019-ncov.pdf
- 547 4. World Health Organization. COVID-19 Weekly Epidemiological Update
 548 [Internet]. World Health Organization; 2023 Mar [cited 2023 Sep 9] p. 19.
 549 Report No.: 134. Available from:
- 550 https://apps.who.int/iris/bitstream/handle/10665/366534/nCoV-weekly-
- 551 sitrep16Mar23-eng.pdf?sequence=1
- 5. Sharaf S, Athikkavil FM, Varghese SD, Sreekumar S, Ramakrishnan R, Varghese
 J, et al. COVID-19: global pandemic with divergent waves: an exigent public
 health concern worldwide with special context to Indian scenario. Int J
- 555 Community Med Public Health. 2022 Feb 28;9(3):1547.
- Dey SK, Rahman MdM, Siddiqi UR, Howlader A, Tushar MdA, Qazi A. Global
 landscape of COVID-19 vaccination progress: insight from an exploratory data
 analysis. Human Vaccines & Immunotherapeutics. 2022 Jan 31;18(1):2025009.
- Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and
 effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and
 COVID-19 cases, hospitalisations, and deaths following a nationwide

34 Manuscript

562 563		vaccination campaign in Israel: an observational study using national surveillance data. The Lancet. 2021 May;397(10287):1819–29.
564 565	8.	Carvalho T, Krammer F, Iwasaki A. The first 12 months of COVID-19: a timeline of immunological insights. Nat Rev Immunol. 2021 Apr;21(4):245–56.
566 567	9.	Domingues CMAS. Desafios para a realização da campanha de vacinação contra a COVID-19 no Brasil. Cad Saúde Pública. 2021;37(1):e00344620.
568 569 570	10.	Oliveira AGD, Silviera D. DESENVOLVIMENTO DE VACINAS CONTRA COVID-19. COOPERAÇÃO OU COMPETIÇÃO INTERNACIONAL? Infarma. 2020 Sep 28;32(3):175–8.
571 572 573	11.	Abreu IR, Alexandre MMM, Costa MCVD, Botelho JMG, Alves LCB, Lima AA. Impact of the COVID-19 pandemic on vaccination coverage in children in Brazil: A literature review. RSD. 2022 Oct 24;11(14):e213111436227.
574 575 576	12.	IBGE. São Gonçalo (RJ) Cidades e Estados IBGE [Internet]. 2024 [cited 2024 Jan 26]. Available from: https://www.ibge.gov.br/cidades-e-estados/rj/sao- goncalo.html
577 578 579	13.	Cleophas TJ, Zwinderman AH. Statistics Applied to Clinical Studies [Internet]. Dordrecht: Springer Netherlands; 2012 [cited 2023 Sep 9]. Available from: http://link.springer.com/10.1007/978-94-007-2863-9
580 581 582	14.	Cham LB, Pahus MH, Grønhøj K, Olesen R, Ngo H, Monrad I, et al. Effect of Age on Innate and Adaptive Immunity in Hospitalized COVID-19 Patients. JCM. 2021 Oct 19;10(20):4798.
583 584	15.	Zhang S, Yang Z, Li ZN, Chen ZL, Yue SJ, Fu RJ, et al. Are Older People Really More Susceptible to SARS-CoV-2? Aging and disease. 2022;13(5):1336.
585 586 587 588	16.	Barnes MPJ. Relationships Between COVID-19 Infection Rates, Healthcare Access, Socioeconomic Status, and Cultural Diversity [Internet] [Master of Science in Mathematics]. [Boise, ID]: Boise State University; 2022 [cited 2023 Oct 25]. Available from: https://scholarworks.boisestate.edu/td/1964/
589 590 591	17.	Luo J, Craver A, Zakin P, Stepniak L, Moore K, King J, et al. Race may modify the association between blood type and COVID-19 infection. eJHaem. 2022 Aug;3(3):903–7.

35 Manuscript

592 593 594 595 596	18.	Robertson M, Shamsunder M, Brazier E, Mantravadi M, Rane MS, Westmoreland DA, et al. Racial/ethnic disparities in exposure to COVID-19, susceptibility to COVID-19 and access to health care - findings from a U.S. national cohort [Internet]. Epidemiology; 2022 Jan [cited 2023 Oct 25]. Available from: http://medrxiv.org/lookup/doi/10.1101/2022.01.11.22269101
597 598 599 600 601	19.	Faberman RJ, Hartley D. The Relationship between Race, Type of Work, and Covid-19 Infection Rates [Internet]. Federal Reserve Bank of Chicago; 2020 [cited 2023 Oct 25]. Available from: https://www.chicagofed.org/~/media/publications/working-papers/2020/ wp2020-18-pdf.pdf
602 603 604	20.	Kimani ME, Sarr M, Cuffee Y, Liu C, Webster NS. Associations of Race/Ethnicity and Food Insecurity With COVID-19 Infection Rates Across US Counties. JAMA Netw Open. 2021 Jun 8;4(6):e2112852.
605 606 607 608	21.	Sobotka T, Brzozowska Z, Muttarak R, Zeman K, Di Lego V. Age, gender and COVID-19 infections [Internet]. Public and Global Health; 2020 May [cited 2023 Oct 25]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.05.24.20111765
609 610 611	22.	Zovi A, Ferrara F, Langella R, Cavallaro F, Vitiello A. Sex affects immune response capacity against COVID-19 infection. Reviews in Medical Virology. 2023 Jul;33(4):e2450.
612 613 614	23.	Chaturvedi R, Lui B, Aaronson JA, White RS, Samuels JD. COVID-19 complications in males and females: recent developments. J Comp Eff Res. 2022 Jun;11(9):689–98.
615 616 617	24.	Oliveira MAD, Haddad A, Godomiczer A, Garcia TR, Sten C, Moisés FP, et al. HYPERTENSION AND RISK FACTOR TO MORTALITY IN CORONAVIRUS DISEASE (COVID-19). Journal of Hypertension. 2023 Jun;41(Suppl 3):e191.
618 619 620	25.	Guan W jie, Liang W hua, Zhao Y, Liang H rui, Chen Z sheng, Li Y min, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020 May;55(5):2000547.
621 622 623	26.	Pavey H, Kulkarni S, Wood A, Ben-Shlomo Y, Sever P, McEniery C, et al. Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank. Karnik SS, editor. PLoS ONE. 2022 Nov 9;17(11):e0276781.

36 Manuscript

27. Zhang J jin, Dong X, Cao Y yuan, Yuan Y dong, Yang Y bin, Yan Y qin, et al.
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan,
China. Allergy. 2020 Jul;75(7):1730–41.

- 627 28. Guan W jie, Ni Z yi, Hu Y, Liang W hua, Ou C quan, He J xing, et al. Clinical
 628 Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr
 629 30;382(18):1708–20.
- Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin
 System Inhibitors With Severity or Risk of Death in Patients With Hypertension
 Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan,
 China. JAMA Cardiol. 2020 Jul 1;5(7):825–30.
- 30. Dahlia D, Artanti KD, Hargono A, Martini S, Nasr NMG, Li CY. Death risk among
 COVID-19 patients with diabetes mellitus. J Public Health Afr [Internet]. 2022
 Dec 7 [cited 2023 Oct 6];13(s2). Available from:
- 637 https://www.publichealthinafrica.org/jphia/article/view/2399
- 538 31. Fadhil Okab H, Khazaal Yassir H, Mohammed Majed M. Estimation of
 539 Immunological and Physiological Parameters in Diabetic Patients with COVID540 19. RB. 2023 Jun 15;8(2):1–4.
- Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes
 mellitus associated with mortality and severity of COVID-19? A meta-analysis.
 Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020
 Jul;14(4):535–45.
- 33. Zahraa ALBasry, Abeer Abdulhadi Rashid, Shaymaa Hasan Abbas. Severity of
 Symptoms and Mortality in Diabetic Patients with COVID- 19 Infection. Review.
 AJPS. 2023 Mar 1;23(1):91–104.
- 548 34. Dallavalasa S, Tulimilli SV, Prakash J, Ramachandra R, Madhunapantula SV,
 549 Veeranna RP. COVID-19: Diabetes Perspective—Pathophysiology and
 550 Management. Pathogens. 2023 Jan 25;12(2):184.
- 451 35. Lima-Martínez MM, Carrera Boada C, Madera-Silva MD, Marín W, Contreras M.
 452 COVID-19 y diabetes mellitus: una relación bidireccional. Clínica e
 453 Investigación en Arteriosclerosis. 2021 May;33(3):151–7.

654	36.	Wong R, Lam E, Bramante CT, Johnson SG, Reusch J, Wilkins KJ, et al. Does
655		COVID-19 Infection Increase the Risk of Diabetes? Current Evidence. Curr Diab
656		Rep. 2023 Aug;23(8):207–16.

37 Manuscript

657	37.	Ribeiro AC, Poli P, Uehara SCDSA. Increased risk of mortality from COVID-19 in
658		people with obesity. Rev Rene. 2023 Jan 24;24:e81453.

- 659 38. Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q, et al. Obesity and COVID-19 Severity
 660 in a Designated Hospital in Shenzhen, China. Diabetes Care. 2020 Jul
 661 1;43(7):1392–8.
- 39. Sattar N, McInnes IB, McMurray JJV. Obesity Is a Risk Factor for Severe COVID19 Infection: Multiple Potential Mechanisms. Circulation. 2020 Jul 7;142(1):4–6.
- 40. Al-Baka HAA, Aldujaili HH. Obesity and Covid-19 Severity. IJFMT [Internet]. 2021
 May 12 [cited 2023 Oct 27]; Available from:
- 666 http://medicopublication.com/index.php/ijfmt/article/view/16267
- 41. Tadayon Najafabadi B, Rayner DG, Shokraee K, Shokraie K, Panahi P, Rastgou P,
 et al. Obesity as an independent risk factor for COVID-19 severity and
 mortality. Cochrane Database Syst Rev. 2023 May 24;5(5):CD015201.
- 42. Mao R, Qiu Y, He JS, Tan JY, Li XH, Liang J, et al. Manifestations and prognosis of
 gastrointestinal and liver involvement in patients with COVID-19: a systematic
 review and meta-analysis. The Lancet Gastroenterology & Hepatology. 2020
 Jul;5(7):667–78.
- 43. Tahvildari A, Arbabi M, Farsi Y, Jamshidi P, Hasanzadeh S, Calcagno TM, et al.
 Clinical Features, Diagnosis, and Treatment of COVID-19 in Hospitalized
 Patients: A Systematic Review of Case Reports and Case Series. Front Med.
 2020 May 15;7:231.
- 44. Yildirim AC, Alkan Ceviker S, Zeren S, Ekici MF, Yaylak F, Algin MC, et al. COVID19 and related gastrointestinal symptoms: An observational study. Marmara
 Medical Journal. 2022 May 30;35(2):244–8.
- 45. Schmeelk S, Davis A, Li Q, Shippey C, Utah M, Myers A, et al. Monitoring
 Symptoms of COVID-19: Review of Mobile Apps. JMIR Mhealth Uhealth. 2022
 Jun 1;10(6):e36065.
- 46. Solehan HM, Mohamed NA, Mohd Rani MD, Ithnin M. Post-COVID-19
 Symptoms, an Online Survey in Malaysia. imjm [Internet]. 2022 Oct 1 [cited
 2023 Oct 28];21(4). Available from:
- 687 https://journals.iium.edu.my/kom/index.php/imjm/article/view/2100

- 38 Manuscript
- 688 47. Orlova NV, Nikiforov VV. An integrated approach to the differential diagnosis of
 689 COVID-19 syndromes and symptoms. Epidemiology and Infectious Diseases.
 690 2022 May 25;26(2):44–56.
- 48. Perrone F, Balbi M, Casartelli C, Buti S, Milanese G, Sverzellati N, et al.
- Differential diagnosis of COVID-19 at the chest computed tomography scan: A
 review with special focus on cancer patients. World J Radiol. 2021 Aug
 28;13(8):243–57.
- 49. Alemi F, Vang J, Wojtusiak J, Guralnik E, Peterson R, Roess A, et al. Differential
 diagnosis of COVID-19 and influenza. Sheel M, editor. PLOS Glob Public Health.
 2022 Jul 21;2(7):e0000221.
- 50. Marginean CM, Popescu M, Vasile CM, Cioboata R, Mitrut P, Popescu IAS, et al.
 Challenges in the Differential Diagnosis of COVID-19 Pneumonia: A Pictorial
 Review. Diagnostics. 2022 Nov 16;12(11):2823.
- 51. Hara M, Furue T, Fukuoka M, Iwanaga K, Matsuishi E, Miike T, et al.
 Comparison of self-reported symptoms in COVID-19 patients who had or had
 not previously received COVID-19 mRNA vaccination. Human Vaccines &
 Immunotherapeutics. 2023 Aug;19(2):2226575.
- 52. Morgan L, Hollist M, Au K, Ayari L, Betts C, Kirmani BF. Neuromuscular
 Disorders Associated With COVID-19. J Exp Neurosci. 2023
 Jan;18:263310552311762.
- 53. Tsukahara T, Brann DH, Datta SR. Mechanisms of SARS-CoV-2-associated
 anosmia. Physiological Reviews. 2023 Oct 1;103(4):2759–66.
- 54. Siena C, Anita B, Sara D GD. Impact of Metabolic Syndrome on Retronasal
 Olfaction. Arch Metabolic Synd [Internet]. 2022 Dec 31 [cited 2024 Jan 29];2(2).
 Available from: https://www.scivisionpub.com/pdfs/impact-of-metabolic-
- 713 syndrome-on-retronasal-olfaction-2517.pdf
- 55. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group
 of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of
 Wuhan, China: retrospective case series. BMJ. 2020 Feb 19;m606.

717	56. Andrews A, C. Mathew A, Mathew T. COVID-19 vaccination status and its effect
718	on outcome and disease severity. Int J Community Med Public Health. 2023 Jan
719	12;10(2):629–34.

- 39 Manuscript
- 720 57. Chahbi Z, Raiteb M, Mouharir M, Belatik I, Badaoui M, Kaddouri S, et al.
- Evolution of COVID-19 According to Vaccination Status in a Moroccan Cohort.
 SAS J Med. 2023 Jun 10;9(06):646–9.
- Furwanti ED, Ronoatmojo S. Association Between COVID-19 Vaccination Status
 With Severity of Confirmed COVID-19 Patients Period of January-July 2022 in
 Indonesia. JIKM. 2023 Mar 30;14(1):13–26.
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety
 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec
 31;383(27):2603–15.

729

730 Supplementary tables

731

Supplementary table 1. Comorbidities present in the sample of participants
 (patients) who were attended at the screening centers of São Gonçalo (RJ), during

the period from 07/28/2021 to 12/02/2021.

Variables	N = 6,953 ¹	
HYPERTENSION		
No	5,652 (82%)	
Yes	1,253 (18%)	
Not available	48	
DIABETES		
No	6,560 (95%)	
Yes	339 (4.9%)	
Not available	54	
OBESITY		
No	6,855 (100%)	
Yes	31 (0.5%)	
Not available	67	
¹ n (%)		